Platinum-based doublet chemotherapy alone or in combination with bevacizumab is the current standard treatment for EGFR-mutated advanced NSCLC with acquired resistance to 3rd-generation EGFR-TKIs (50–52), and immunotherapy is becoming the new direction for next-line treatment of NSCLC patients following resistance to EGFR-TKIs, notably among those with unknow mechanisms of resistance (53, 54). This evidence concerns the gene EGFR and non-small cell lung carcinoma.